A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi, Zhang, Hao, Shi, Junfeng, Wang, Tongshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721275/
https://www.ncbi.nlm.nih.gov/pubmed/33299330
http://dx.doi.org/10.2147/OTT.S279004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721275/
https://www.ncbi.nlm.nih.gov/pubmed/33299330
http://dx.doi.org/10.2147/OTT.S279004

Ejemplares similares